Enveric Biosciences Inc 2024年度报告

FORM10-K☒Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934For the annual period ended:December 31,2024OR☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ENVERIC BIOSCIENCES, INC.(Exact name of registrant as specified in its charter) (239)302-1707(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act: Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation of its management’s assessment of the effectiveness of itsinternal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report.☐ If the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of June 30, 2024, the last day of the registrant’s most recently completed second fiscal quarter; the aggregate market value of theregistrant’s common stock held by non-affiliates of the registrant, based on a closing price of $9.39 per share, was approximately $4.9million. As of March 27, 2025, there were2,471,656shares outstanding of Registrant’s Common Stock (par value $0.01per share). DOCUMENTS INCORPORATED BY REFERENCE Portions of the Company’s proxy statement for the Annual Meeting of Stockholders to be held May 29, 2025 are incorporated by referenceinto Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’sfiscal year ended December 31, 2024. Additionally, portions of the Annual Report are incorporated by reference in this Form 10-K in responseto Items within Part II. ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES FORM 10-K TABLE OF CONTENTS PagePART I - FINANCIAL INFORMATIONItem 1.Business4Item 1A.Risk Factors16Item 1B.Unresolved Staff Comments45Item 1C.Cybersecurity45Item 2.Properties45Item 3.Legal Proceedings45Item 4.Mine Safety Disclosures45PART II - OTHER INFORMATIONItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities46Item 6.[Reserved]46Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations47Item 7A.Quantitative and Qualitative Disclosure About Market Risk54Item 8.Financial Statements and Supplementary Data54Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure54Item 9A.Controls and Procedures55Item 9B.Other Information56Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections56PART IIIItem 10.Directors, Executive Officers and Corpo